Visit website provides authoritative, independent and innovative online news coverage of the biopharmaceutical industry. Across written, visual and audio formats it covers the key trends, challenges and dynamics specific to the biopharmaceutical world.

  • Unique coverage of and exclusive insight into core topics.
  • The latest technological breakthroughs in upstream and downstream processing.
  • Bio developments and technologies.

Key Contacts

Melissa Fassbender Editor Tel: +1312 2848590 Email: 

Latest industry news from

More news


A troubled timeline of Alzheimer’s trials

After Biogenâs setback in the space, the number of treatments that have not succeeded in making an impact on Alzheimerâs disease continues to grow.


Biogen value drops by $18bn after Alzheimer’s drug failure

Biogen and its partner, Eisai, confirm a decision to stop the Phase III development of aducanumab, a potential treatment for Alzheimerâs â a key part of the formerâs pipeline.


Pfizer secures option to acquire Vivet for up to $635.8m

Pfizer secures an exclusive option to acquire Vivet for up to $635.8m after collaborating with the biotech to develop an AAV gene therapy treatment.


WuXi Biologics becomes first Chinese EU approved CDMO

WuXi Biologics receives EMA GMP certification for the production of Trogarzo at its manufacturing facilities in Wuxi city and Shanghai, China.


Abzena tapped as CMC for Lipum’s biologic development project

Abzena and Lipum enter agreement for the development of biologics for juvenile idiopathic arthritis, using the formerâs proprietary cell line and GMP resources.


Takeda’s plasma manufacturing facility approved by FDA

US FDA approves Takedaâs acquired plasma manufacturing facility in Georgia, US, for the production of flexbumin 25% solution.


Authorities raid Korean stock exchange over Samsung BioLogics IPO

Korean authorities continue to place pressure on the CDMO, after prosecutors raided the office of the national stock exchange regarding behaviour preceding the public listing of Samsung BioLogics.


Vertex receives approval and develops triple combination gene therapy for CF

Vertexâs Symdeko approved in Australia, after FDA approval in 2018, as the company works to develop triple combination gene therapies for CF.


Technology boosts access to biologics and insulin via oral delivery

Drug delivery of biologics takes a sharp turn, as the development of pills that can replace injections and increase drug accessibility moves forward.


First mAb biosimilar from Pfizer approved by FDA

US FDA approves Pfizerâs Trazimera, a biosimilar to Rocheâs blockbuster product, Herceptin, for the treatment of HER2 positive breast cancer.

Related Brands

Back to brands